#cannabisaficionado

Sports

Aurora & UFC Are Researching the Benefits of CBD for MMA Fighters

Published

on

UFC
PHOTO | dusanpetkovic1
Advertisement Back2Grow Advertisement

Sometimes you can clearly see how much progress has been made with breaking the stigma around cannabis. Only a few years ago, Nate Diaz threw the mixed martial arts community into a frenzy by openly hitting a vape filled with CBD oil on stage during his post-match interview with Conor McGregor. 

“It’s CBD,” Diaz told the press when asked about the device. “It helps with the healing process and inflammation, stuff like that. So you want to get these for before and after the fights, training. It’ll make your life a better place.”

While Diaz was absolutely right about the anti-inflammatory and pain management benefits of CBD, that didn’t stop the World Anti-Doping Agency (WADA), USADA and UFC anti-doping from collectively losing their shit over it. 

Diaz was facing a suspension and a possible ban from the sport similar to his older brother Nick. 

Today, things look much, much different when it comes to CBD. 

After the WADA removed CBD from their banned substances list about a year ago, the UFC has now penned a multi-year, multi-million dollar partnership with Aurora Cannabis Inc. to research the health benefits of CBD for MMA fighters. 

The studies will test out the effects of hemp-derived CBD for wound-healing, pain management, inflammation control and overall recovery on top-class MMA athletes over the next eight years.  

The research will be conducted in the UFC’s own Performance Institute in Las Vegas, testing the effects on athletes who volunteer to participate in the study by Institute staff. Aurora’s research will be led by Dr. Jason Dyck, a professor at the University of Alberta, a Canada Research Chair in Molecular Medicine and an independent director on the board at Aurora Cannabis. 

In a statement, officials for both UFC and Aurora expressed their excitement over the partnership. 

“This partnership with Aurora is an extension of that goal, and we’re looking forward to collaborating with Aurora to find new ways to improve the health and safety of athletes who compete in UFC,” said UFC President Dana White.

Terry Booth, CEO of Aurora added, “This global partnership places focus squarely on the health and well-being of UFC’s talented and highly trained athletes. The Aurora-UFC research partnership creates a global platform to launch targeted educational and awareness campaigns, while creating numerous opportunities to accelerate our global CBD business.”

White told the press at a joint press conference between the two he believes about half of all elite athletes use some sort of CBD-based product for recovery that this partnership will make sure those products are safe and authentic, paving the way for future products will help prevent the use “untested CBD treatments,” and will be used during practice, before and after a match. 

“The focus is going to be on research, safety, health, and the well being of our athletes,” White said.

It’s well-known how many big-name UFC athletes have been open and clear about their support of not only CBD-based products for recovery but cannabis as a whole. This new partnership could open the doors to more athletes exploring natural, opiate-free alternatives than ever before without the fear of sanctions, suspensions and punishment in one of the most brutal sports around. 

Sports

Josh Myers’ Cannabis Ruling Shows How Racing Handles an Unfamiliar Vape

The original November 16 decision explains a two-month licence withdrawal, an unfamiliar vape and the duties attached to racing’s testing rules.

Published

on

Three jockeys racing brown horses on a grass track.

British racing’s independent disciplinary panel has ordered a two-month withdrawal of amateur jockey Josh Myers’ licence after a cannabis-positive sample. The decision, published November 16, dates the penalty from his interim suspension on September 23. It is a ruling on a rider’s anti-doping obligations, not a finding that a horse tested positive or a general rule applying identically across all sports.

The cannabis connection is explicit: Myers admitted breaching the rule requiring jockeys to ensure no banned substance is present in their bodies. The case also turns attention to an unfamiliar vape, disclosure after learning what it contained, and the difference between explaining exposure and avoiding responsibility under a sporting rule.

The panel’s account of the case

The original decision records a post-race urine test following Myers’ ride on The Pug at Brighton on August 23. The sample contained THC-acid above the applicable confirmation level. The panel set out his explanation that he had used a friend’s vape two days earlier without initially knowing the liquid contained cannabis.

According to that account, he learned its contents after experiencing effects. The decision records that he did not alert the BHA before testing, despite then knowing there could be a risk. The testing laboratory considered his explanation plausible; that assessment did not eliminate the rule breach.

These points should be read together. The decision accepted an account of inadvertent initial use while still imposing a penalty. It does not establish that every cannabis-positive test has the same explanation, nor that borrowing any particular kind of vape necessarily produces this result.

Why knowing use was not required

The decision sets out Rules K49 and K50: the presence obligation does not depend on proving intent, fault, negligence or knowing use. That is the strict-liability feature relevant to this case. An explanation of how exposure occurred can matter to the circumstances and penalty without disproving the presence of a banned substance.

The panel approved the agreed fast-track resolution and considered cooperation, admissions and Myers’ previous disciplinary record. The two-month period runs from the interim suspension, rather than beginning afresh on the publication date. Readers should avoid adding an extra two months to the announced decision or assuming the report itself establishes a later return to competition.

There is also a distinction between what a laboratory measurement can show and what the sport decides to prohibit. The ruling reports a metabolite result and applies the relevant rules. It should not be converted into an independent diagnosis of the rider’s degree of impairment during the race.

Racing places safety at the center

The BHA’s human anti-doping guidance says its regulations apply to licensed jockeys regardless of competitive level. It describes protection of riders, horses and sporting ethics as the aims of control. Cannabis is among the substances discussed in its explanation of performance-inhibiting risks.

That framing is important in a sport involving other riders and animals. A question about reaction, judgment or safe participation is different from the narrower popular debate over whether cannabis can improve an athletic result. A substance does not have to be described as a performance enhancer for a regulator to restrict it.

The guidance also directs riders to the jockey testing code and medication rules. Someone competing under those rules needs to consult that framework, rather than relying on a retailer’s product description, a friend’s assurance or an account of another athlete’s case. Rules governing human participants should also be kept separate from equine testing requirements.

One sporting system does not stand for all

Our coverage of Owen Trout’s rugby league case examined a different anti-doping framework. The useful connection is the need to identify the governing rules before drawing conclusions. A sanction in racing cannot simply be substituted for a rugby sanction because both involve a cannabis metabolite.

For athletes, the practical reading of the Myers decision begins with product uncertainty and continues with the sport’s disclosure and testing obligations. An ingredient’s legal availability and an athlete’s eligibility are separate questions. Likewise, accepting an exposure explanation is different from accepting that the athlete met every applicable requirement.

The ruling identifies a confirmation level of 15 nanograms per millilitre and reports a sample concentration above 100. These are the decision’s testing figures, not instructions for calculating a safe waiting period. Neither a concentration from one case nor the timing of that rider’s reported exposure supplies a reliable timetable for another person to pass a test.

The new ruling supplies a concrete example of those distinctions. It records an admitted breach, the explanation considered, and the penalty imposed through the fast-track procedure. Keeping those elements separate allows a more accurate discussion of cannabis in sport than treating every positive test as either deliberate cheating or an event with no regulatory consequences.

Illustrative horse-racing stock photograph; not Josh Myers, The Pug or Brighton Racecourse. Photo: Aliaksei Semirski / Pexels.

Continue Reading

Sports

Cannabis-and-Tobacco Recovery Study Finds Similar Patterns, With Important Limits

A November pilot study followed 26 active adults after a muscle-damaging exercise protocol. Its findings leave key questions about cannabis alone unanswered.

Published

on

A black hexagonal dumbbell casting a shadow across a gym floor.

A small study published online November 6 in Biology of Sport found broadly similar short-term recovery patterns after strenuous exercise among regular cannabis-and-tobacco co-users and comparison participants. The finding adds evidence to a specific sports-science question, but does not demonstrate that cannabis improves recovery or establish a safe dose for training.

The distinction matters for cannabis consumers who see recovery claims attached to workout products. Observing how existing users recover is different from giving a standardized cannabis product to randomly assigned participants and measuring its effects. This paper concerns the former question, with tobacco use adding another complication.

What the pilot study measured

Antoine Mendes and colleagues studied 26 physically active adults: 12 regular cannabis users and 14 non-users. The users predominantly consumed THC-dominant cannabis mixed with tobacco. Participants performed a drop-jump protocol, with muscle function, soreness and blood markers followed through 72 hours. The open-access paper is available through HAL; the journal record gives the November publication date and its 2027 issue citation.

The groups showed broadly similar concentric strength, muscle-damage marker and soreness responses. Some isometric strength differences appeared at individual time points. The authors identify a small sample, variable self-reported cannabis exposure and residual tobacco confounding as limitations. Acute and chronic cannabis effects could not be separated.

Those qualifications belong beside the result. A study of combined exposure cannot isolate a cannabis-only effect, and measurements over three days cannot establish what happens across months of training. Nor does an isolated difference on one strength measure justify describing cannabis as a recovery treatment.

The sample also comprised 20 men and six women, recruited as physically active students. That population limits how confidently the result can be extended to older adults, people managing injuries or elite competitors. The experiment did not compare every route of cannabis administration. A result involving habitual users of cannabis mixed with tobacco cannot simply be transferred to an edible, a vaporizer or a CBD-only topical.

Why similar results are not proof of a benefit

A finding of no clear difference answers a narrower question than a finding of equivalence. With a small group, uncertainty remains around effects that the experiment may not detect. Readers should therefore resist translating similar average patterns into a universal statement that cannabis has no consequences for every athlete.

The same restraint applies in the other direction. A statistically notable measurement is not automatically a meaningful improvement in sporting performance. Recovery, pain perception, strength and competition results are related ideas, but they are not interchangeable outcomes. This study cannot be used as a shortcut between them.

For a coach or recreational athlete, a useful reading starts with the population, exposure, comparison and follow-up. Ask who participated, what they actually used, whether exposure was controlled and what the researchers measured. Those questions reveal how far a headline can travel beyond the underlying experiment.

Recovery evidence does not settle training safety

The CDC’s cannabis and brain-health guidance describes effects on attention, coordination, movement and reaction time. It also notes that factors including THC concentration, frequency of use and other substances influence effects. Those considerations are separate from whether a particular muscle marker returns toward baseline after exercise.

That separation is practical. A laboratory recovery result does not tell someone whether they can safely handle equipment while impaired, drive home or make decisions during a demanding session. The paper should be read as research on measured recovery outcomes, rather than permission to disregard those other questions.

It is also distinct from a product efficacy claim. FDA’s cannabis guidance distinguishes approved medicines from unapproved products marketed with therapeutic claims. A published study is not itself FDA approval of a gummy, topical or recovery supplement, especially when the marketed product was never tested in that experiment.

Athletes have another rulebook to check

Drug-testing obligations remain a separate consideration. USADA’s advisory on the 2027 prohibited list says its changes take effect January 1, 2027. It describes in-competition restrictions on psychoactive cannabis components and compounds that mimic THC, while warning that CBD products can contain THC that creates a positive-test risk.

Those future rules should not be confused with the rules applicable before their effective date, and individual sports may operate under different policies. Athletes need to check the rules that govern their own competition rather than infer eligibility from a recovery paper or a product’s legal retail availability.

Our earlier explanation of the 2027 cannabis rulebook examines that distinction. This new study contributes a different piece of the discussion: limited human data on recovery, with uncertainties that remain essential to interpreting the result.

Illustrative gym stock photograph; not equipment or participants from the study. Photo: Hebert Santos / Pexels.

Continue Reading

Sports

Las Vegas Grand Prix Returns This Week With a Cannabis Ban at the Circuit

Race weekend returns to the Strip November 19–21, but state cannabis access and permission inside the circuit are separate questions.

Published

on

Night view of Las Vegas with MGM Grand and the illuminated Luxor pyramid

The Las Vegas Grand Prix returns November 19–21, turning the Strip into a race-week destination again. For cannabis consumers traveling to Nevada, the important preparation is straightforward: legal adult-use access in the state does not mean marijuana is permitted inside the event. The promoter’s entry conditions and Nevada’s consumption rules address different parts of the visit.

The official race FAQ confirms the three-day dates and the street circuit’s location around Las Vegas Boulevard, Harmon Avenue, Koval Lane and Sands Avenue. It also identifies F1 Academy as a support series this year. This is a preview of the coming weekend, rather than a report on results or a suggestion that any driver uses cannabis.

The ticket terms address possession at entry

The promoter’s ticket terms explicitly include marijuana among items guests may not bring onto the circuit grounds or possess while seeking entry. That restriction is broader than a rule about lighting up in a seat. Changing the form of a marijuana product does not create an exception in the published entry language.

The terms also allow inspection of guests and belongings. Prohibited items can lead to refused entry or removal, and surrendered items may be disposed of. Visitors should settle the question before approaching a gate, instead of expecting security staff to provide storage or make an exception because a product was bought legally.

A medical recommendation should not be treated as an automatic override. The event’s separate instructions for prescription medication concern labeled containers and medical clearance; they do not expressly waive its marijuana prohibition. Anyone with a specific accommodation question should ask the organizer before travel and obtain a clear answer about the relevant product and circumstances.

A smoking area does not mean a cannabis area

The A–Z visitor guide is more specific than a general reference to smoking areas. It prohibits marijuana smoking or vaping anywhere within the event. Authorized smoking areas are for tobacco. General Admission, grandstands and hospitality spaces are among the viewing areas covered by the broader smoking restrictions.

That wording matters when an event offers several kinds of space. An outdoor setting, a private suite or a location marked for smoking does not establish permission to consume cannabis. The useful source is the current substance-specific policy, rather than a photograph of an open-air grandstand or someone else’s experience at another sporting event.

Our reporting on NYRR’s cannabis smoking rule illustrates the same need to read an organizer’s own conditions. The Las Vegas policy stands on its own; rules from a different competition cannot be carried across to this one.

Nevada access comes with location restrictions

The Nevada Cannabis Compliance Board’s public guidance says retail customers must be at least 21 and buy from a state-licensed store. It separately prohibits cannabis use in public places and moving vehicles, including by passengers. Private-property consumption depends on the owner permitting it; licensed consumption lounges provide another authorized setting.

Those distinctions make accommodation planning important. A hotel reservation is not evidence that cannabis use is allowed in the room, and a legal retail purchase does not authorize consumption during a ride to the circuit. Checking the property’s policy and the status of any proposed venue is part of planning the visit.

Nevada’s adult-use statute also sets particular rules for consumption lounges, including excluding people under 21 and keeping consumption out of public view. A lounge is a separately regulated business, not an extension of a race ticket. Its existence does not change what the promoter allows inside the event perimeter.

Plan the route as carefully as the ticket

Clark County’s race information confirms the November 19–21 return and links an interactive circuit-preparation timeline and map. Road access changes are a practical reason to check an up-to-date route, even for visitors who already know the Strip.

The organizer directs ticketholders to zone-specific entrance information and the official app’s map. The A–Z guide says there are no lockers and no re-entry after 7 p.m. Pacific each evening. A plan that depends on leaving an item at the gate or casually stepping out and back in may therefore fail.

The guide also identifies medical locations and says water is complimentary at beverage concessionaire tents. Earplugs are available on request at medical, guest-services and accessibility locations. These are useful details to save before arriving, alongside the entrance map and ticket. They address the practical experience of attending a loud, busy race weekend without implying that a cannabis purchase is part of that experience.

The clearest approach is to separate the day’s decisions: where the ticket permits entry, what the event permits guests to carry, where Nevada permits consumption and how the visitor will travel safely. Sorting out those boundaries before race weekend leaves more attention for the racing once the gates open.

Stock photograph of Las Vegas; not a photograph of the 2026 Grand Prix or its race circuit. Photo: Luis Pelegrin / Pexels.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.